BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lam RW, McIntosh D, Wang J, Enns MW, Kolivakis T, Michalak EE, Sareen J, Song WY, Kennedy SH, MacQueen GM, Milev RV, Parikh SV, Ravindran AV; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care. Can J Psychiatry 2016;61:510-23. [PMID: 27486151 DOI: 10.1177/0706743716659416] [Cited by in Crossref: 141] [Cited by in F6Publishing: 115] [Article Influence: 23.5] [Reference Citation Analysis]
Number Citing Articles
1 Fonseka TM, MacQueen GM, Kennedy SH. Neuroimaging biomarkers as predictors of treatment outcome in Major Depressive Disorder. J Affect Disord 2018;233:21-35. [PMID: 29150145 DOI: 10.1016/j.jad.2017.10.049] [Cited by in Crossref: 76] [Cited by in F6Publishing: 58] [Article Influence: 15.2] [Reference Citation Analysis]
2 Lauzier S, Kadachi H, Moisan J, Vanasse A, Lesage A, Fleury MJ, Grégoire JP. Neighbourhood Material and Social Deprivation and Exposure to Antidepressant Drug Treatment: A Cohort Study Using Administrative Data. Can J Psychiatry 2018;63:701-11. [PMID: 29514506 DOI: 10.1177/0706743718760290] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhao Q, Fan HZ, Li YL, Liu L, Wu YX, Zhao YL, Tian ZX, Wang ZR, Tan YL, Tan SP. Vocal Acoustic Features as Potential Biomarkers for Identifying/Diagnosing Depression: A Cross-Sectional Study. Front Psychiatry 2022;13:815678. [PMID: 35573349 DOI: 10.3389/fpsyt.2022.815678] [Reference Citation Analysis]
4 Duan L, Gao Y, Shao X, Tian C, Fu C, Zhu G. Research on the Development of Theme Trends and Changes of Knowledge Structures of Drug Therapy Studies on Major Depressive Disorder Since the 21st Century: A Bibliometric Analysis. Front Psychiatry 2020;11:647. [PMID: 32754061 DOI: 10.3389/fpsyt.2020.00647] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Glowacki K, Arbour-nicitopoulos K, Burrows M, Chesick L, Heinemann L, Irving S, Lam RW, Macridis S, Michalak E, Scott A, Taylor A, Faulkner G. It's more than just a referral: Development of an evidence-informed exercise and depression toolkit. Mental Health and Physical Activity 2019;17:100297. [DOI: 10.1016/j.mhpa.2019.100297] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
6 Feng X, Fan Y, Chung CY. Mefenamic acid can attenuate depressive symptoms by suppressing microglia activation induced upon chronic stress. Brain Res 2020;1740:146846. [PMID: 32325074 DOI: 10.1016/j.brainres.2020.146846] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Sims-Gould J, Vazirian S, Li N, Remick R, Khan K. Jump step - a community based participatory approach to physical activity & mental wellness. BMC Psychiatry 2017;17:319. [PMID: 28859610 DOI: 10.1186/s12888-017-1476-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
8 Solmi M, Miola A, Croatto G, Pigato G, Favaro A, Fornaro M, Berk M, Smith L, Quevedo J, Maes M, Correll CU, Carvalho AF. How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. Braz J Psychiatry 2021;43:189-202. [PMID: 32491040 DOI: 10.1590/1516-4446-2020-0935] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Huang L, Huang R, Fei Y, Liu T, Mellor D, Xu W, Xiong J, Mao R, Chen J, Fang Y, Wu Z, Wang Z. Lower Health Literacy of Mania Than Depression Among Older People: A Random Survey of a Community Healthcare Service Center. Front Psychiatry 2021;12:512689. [PMID: 33776809 DOI: 10.3389/fpsyt.2021.512689] [Reference Citation Analysis]
10 Kaster TS, Vigod SN, Gomes T, Wijeysundera DN, Blumberger DM, Sutradhar R. A practical overview and decision tool for analyzing recurrent events in mental illness: A review. J Psychiatr Res 2021;137:7-13. [PMID: 33636563 DOI: 10.1016/j.jpsychires.2021.02.031] [Reference Citation Analysis]
11 Santina T, Lauzier S, Gagnon H, Villeneuve D, Moisan J, Grégoire JP, Guillaumie L. The Development of a Community Pharmacy-Based Intervention to Optimize Patients' Use of and Experience with Antidepressants: A Step-by-Step Demonstration of the Intervention Mapping Process. Pharmacy (Basel) 2018;6:E39. [PMID: 30720782 DOI: 10.3390/pharmacy6020039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Han C, Wang G, Chan S, Kato T, Ng CH, Tan W, Zhang L, Feng Y, Liu CY. Definition and Identification of Patients with Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia. Neuropsychiatr Dis Treat 2020;16:2929-41. [PMID: 33311981 DOI: 10.2147/NDT.S264799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Miron JP, Voetterl H, Fox L, Hyde M, Mansouri F, Dees S, Zhou R, Sheen J, Desbeaumes Jodoin V, Mir-Moghtadaei A, Blumberger DM, Daskalakis ZJ, Vila-Rodriguez F, Downar J. Optimized repetitive transcranial magnetic stimulation techniques for the treatment of major depression: A proof of concept study. Psychiatry Res 2021;298:113790. [PMID: 33581379 DOI: 10.1016/j.psychres.2021.113790] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
14 Howren A, Aviña-Zubieta JA, Da Costa D, Puyat JH, Xie H, De Vera MA. Impact of arthritis on the perceived need and use of mental healthcare among Canadians with mental disorders: nationally representative cross-sectional study. BMJ Open 2020;10:e041371. [PMID: 33303458 DOI: 10.1136/bmjopen-2020-041371] [Reference Citation Analysis]
15 Wells H, Crowe M, Inder M. Why people choose to participate in psychotherapy for depression: A qualitative study. J Psychiatr Ment Health Nurs 2020;27:417-24. [PMID: 31957177 DOI: 10.1111/jpm.12597] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Meltzer-Brody S, Howard LM, Bergink V, Vigod S, Jones I, Munk-Olsen T, Honikman S, Milgrom J. Postpartum psychiatric disorders. Nat Rev Dis Primers 2018;4:18022. [PMID: 29695824 DOI: 10.1038/nrdp.2018.22] [Cited by in Crossref: 69] [Cited by in F6Publishing: 57] [Article Influence: 17.3] [Reference Citation Analysis]
17 Wang G, Han C, Liu CY, Chan S, Kato T, Tan W, Zhang L, Feng Y, Ng CH. Management of Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia. Neuropsychiatr Dis Treat 2020;16:2943-59. [PMID: 33299316 DOI: 10.2147/NDT.S264813] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Yrondi A, Bennabi D, Haffen E, Garnier M, Bellivier F, Bourgerol T, Camus V, D'Amato T, Doumy O, Haesebaert F, Holtzmann J, Lançon C, Vignaud P, Moliere F, Nieto I, Richieri RM, Domenech P, Rabu C, Mallet L, Yon L, Schmitt L, Stephan F, Vaiva G, Walter M, Llorca PM, Courtet P, Leboyer M, El-Hage W, Aouizerate B. Significant Need for a French Network of Expert Centers Enabling a Better Characterization and Management of Treatment-Resistant Depression (Fondation FondaMental). Front Psychiatry 2017;8:244. [PMID: 29225582 DOI: 10.3389/fpsyt.2017.00244] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
19 Hu YT, Hu XW, Han JF, Zhang JF, Wang YY, Wolff A, Tremblay S, Tan ZL, Northoff G. Childhood trauma mediates repetitive transcranial magnetic stimulation efficacy in major depressive disorder. Eur Arch Psychiatry Clin Neurosci 2021. [PMID: 34117915 DOI: 10.1007/s00406-021-01279-3] [Reference Citation Analysis]
20 Shamabadi A, Akhondzadeh S. Efficacy and tolerability of Lavandula angustifolia in treating patients with the diagnosis of depression: a systematic review of randomized controlled trials. J Complement Integr Med 2021. [PMID: 34420270 DOI: 10.1515/jcim-2020-0498] [Reference Citation Analysis]
21 Dobson KG, Vigod SN, Mustard C, Smith PM. Major Depressive Episodes and Employment Earnings Trajectories over the Following Decade among Working-aged Canadian Men and Women. J Affect Disord 2021;285:37-46. [PMID: 33626409 DOI: 10.1016/j.jad.2021.02.019] [Reference Citation Analysis]
22 Everitt N, Broadbent J, Richardson B, Smyth JM, Heron K, Teague S, Fuller-Tyszkiewicz M. Exploring the features of an app-based just-in-time intervention for depression. J Affect Disord 2021;291:279-87. [PMID: 34058610 DOI: 10.1016/j.jad.2021.05.021] [Reference Citation Analysis]
23 Haro JM, Hammer-Helmich L, Saragoussi D, Ettrup A, Larsen KG. Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study. Neuropsychiatr Dis Treat 2019;15:2313-23. [PMID: 31616147 DOI: 10.2147/NDT.S206825] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
24 Doron R, Versano Z, Burstein O, Franko M, Shamir A, Toledano R, Handelsman A, Rehavi M. Cerebral MAO Activity Is Not Altered by a Novel Herbal Antidepressant Treatment. J Mol Neurosci 2019;69:371-9. [PMID: 31290092 DOI: 10.1007/s12031-019-01366-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Swainson J, Klassen LJ, Brennan S, Chokka P, Katzman MA, Tanguay RL, Khullar A. Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing. CNS Drugs 2022. [PMID: 35165841 DOI: 10.1007/s40263-022-00897-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Wu H, Xu L, Zheng Y, Shi L, Zhai L, Xu F. Application of the Delphi Method in the Study of Depressive Disorder. Front Psychiatry 2022;13:925610. [DOI: 10.3389/fpsyt.2022.925610] [Reference Citation Analysis]
27 Oluboka OJ, Katzman MA, Habert J, McIntosh D, MacQueen GM, Milev RV, McIntyre RS, Blier P. Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient. Int J Neuropsychopharmacol 2018;21:128-44. [PMID: 29024974 DOI: 10.1093/ijnp/pyx081] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
28 Sparling JE, Barbeau K, Boileau K, Konkle ATM. Environmental enrichment and its influence on rodent offspring and maternal behaviours, a scoping style review of indices of depression and anxiety. Pharmacol Biochem Behav 2020;197:172997. [PMID: 32702399 DOI: 10.1016/j.pbb.2020.172997] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
29 Tong P, Bo P, Shi Y, Dong L, Sun T, Gao X, Yang Y. Clinical traits of patients with major depressive disorder with comorbid borderline personality disorder based on propensity score matching. Depress Anxiety 2021;38:100-6. [PMID: 33326658 DOI: 10.1002/da.23122] [Reference Citation Analysis]
30 Jones AM, Koehoorn M, Bültmann U, McLeod CB. Pre-existing anxiety and depression disorders and return to work after musculoskeletal strain or sprain: a phased-based approach. J Occup Rehabil 2022. [PMID: 35666362 DOI: 10.1007/s10926-022-10047-6] [Reference Citation Analysis]
31 Jones AM, Koehoorn M, Bültmann U, McLeod CB. Impact of anxiety and depression disorders on sustained return to work after work-related musculoskeletal strain or sprain: a gender stratified cohort study. Scand J Work Environ Health 2021;47:296-305. [PMID: 33744976 DOI: 10.5271/sjweh.3951] [Reference Citation Analysis]
32 Lemieux S, Tourigny M, Joly J, Baril K, Séguin M. Caractéristiques associées à la dépression et aux symptômes de stress post-traumatique chez les femmes victimes d’agression sexuelle durant l’enfance. Revue d'Épidémiologie et de Santé Publique 2019;67:285-94. [DOI: 10.1016/j.respe.2019.05.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Kennedy SH, Ceniti AK. Unpacking Major Depressive Disorder: From Classification to Treatment Selection. Can J Psychiatry 2018;63:308-13. [PMID: 29278937 DOI: 10.1177/0706743717748883] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
34 Guimarães MC, Guimarães TM, Hallak JE, Abrão J, Machado-de-Sousa JP. Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial. Braz J Psychiatry 2021;43:484-93. [PMID: 33605397 DOI: 10.1590/1516-4446-2020-1543] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Soares CN, Zhang M, Boucher M. Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine. CNS Spectr 2019;24:322-32. [PMID: 29140227 DOI: 10.1017/S1092852917000633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
36 Middleton JC, Kalogeropoulos C, Middleton JA, Drapeau M. Assessing the methodological quality of the Canadian Psychiatric Association's anxiety and depression clinical practice guidelines. J Eval Clin Pract 2019;25:613-21. [DOI: 10.1111/jep.13026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
37 Otheman Y, Fakir A, Kadiri M, Bichra MZ. [Frequency of physical symptoms in anxiety-depressive disorders: cross-sectional study in a population of 202 psychiatric consultants]. Pan Afr Med J 2018;31:149. [PMID: 31037209 DOI: 10.11604/pamj.2018.31.149.15738] [Reference Citation Analysis]
38 Lee J, Gierc M, Vila-Rodriguez F, Puterman E, Faulkner G. Efficacy of exercise combined with standard treatment for depression compared to standard treatment alone: A systematic review and meta-analysis of randomized controlled trials. J Affect Disord 2021;295:1494-511. [PMID: 34565591 DOI: 10.1016/j.jad.2021.09.043] [Reference Citation Analysis]
39 Perlman K, Benrimoh D, Israel S, Rollins C, Brown E, Tunteng J, You R, You E, Tanguay-sela M, Snook E, Miresco M, Berlim MT. A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder. Journal of Affective Disorders 2019;243:503-15. [DOI: 10.1016/j.jad.2018.09.067] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 17.0] [Reference Citation Analysis]
40 Dodd S, Bauer M, Carvalho AF, Eyre H, Fava M, Kasper S, Kennedy SH, Khoo J, Lopez Jaramillo C, Malhi GS, Mcintyre RS, Mitchell PB, Castro AMP, Ratheesh A, Severus E, Suppes T, Trivedi MH, Thase ME, Yatham LN, Young AH, Berk M. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough? The World Journal of Biological Psychiatry 2021;22:483-94. [DOI: 10.1080/15622975.2020.1851052] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
41 Zhou Y, Ma Y, Wu Q, Wang Q, Yang WFZ, Wang Y, Yang D, Luo Y, Tang K, Liu T, Wang D. Comparison of Thyroid Hormone Levels Between Patients With Major Depressive Disorder and Healthy Individuals in China. Front Psychiatry 2021;12:750749. [PMID: 34721116 DOI: 10.3389/fpsyt.2021.750749] [Reference Citation Analysis]
42 Al Shirawi MI, Edgar NE, Kennedy SH. Brexpiprazole in the Treatment of Major Depressive Disorder. Clinical Medicine Insights: Therapeutics 2017;9:1179559X1773180. [DOI: 10.1177/1179559x17731801] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
43 Wang Z, Li X, Li N, Huang L, Liu J, Yang B, Shi J, Fei Y, Ji X, Gao K, Ren M. Safety and Tolerability of Both Arm Ischemic Conditioning in Patients With Major Depression: A Proof of Concept Study. Front Psychiatry 2020;11:570. [PMID: 32625124 DOI: 10.3389/fpsyt.2020.00570] [Reference Citation Analysis]
44 Choi W, Stewart R, Kang HJ, Kim JW, Kim HK, Kang HC, Lee JY, Kim SW, Kim JM. Interactive effects of systemic inflammation and life stressors on treatment response of depressive disorders. Brain Behav Immun 2021;95:61-7. [PMID: 33548497 DOI: 10.1016/j.bbi.2021.01.029] [Reference Citation Analysis]
45 Lauzier S, Guillaumie L, Humphries B, Grégoire JP, Moisan J, Villeneuve D. Psychosocial factors associated with pharmacists' antidepressant drug treatment monitoring. J Am Pharm Assoc (2003) 2020;60:548-58. [PMID: 32173335 DOI: 10.1016/j.japh.2020.01.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Cook IA, Hunter AM, Caudill MM, Abrams MJ, Leuchter AF. Prospective testing of a neurophysiologic biomarker for treatment decisions in major depressive disorder: The PRISE-MD trial. J Psychiatr Res 2020;124:159-65. [PMID: 32169689 DOI: 10.1016/j.jpsychires.2020.02.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Lachaine J, Beauchemin C, Bibeau J, Patenaude J, Chokka P, Proulx J, Bougie J. Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine. CNS Spectr 2020;25:372-9. [PMID: 31120009 DOI: 10.1017/S1092852919000853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Sarfati D, Evans VC, Tam EM, Woo C, Iverson GL, Yatham LN, Lam RW. The impact of fatigue and energy on work functioning and impairment in patients with major depressive disorder treated with desvenlafaxine. Int Clin Psychopharmacol 2017;32:343-9. [PMID: 28763344 DOI: 10.1097/YIC.0000000000000192] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
49 Adhikari K, Patten SB, Lee S, Metcalfe A. Adherence to and Persistence with Antidepressant Medication during Pregnancy: Does It Differ by the Class of Antidepressant Medication Prescribed? Can J Psychiatry 2019;64:199-208. [PMID: 30252505 DOI: 10.1177/0706743718802809] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
50 Bogucki OE, Craner JR, Berg SL, Miller SJ, Wolsey MK, Smyth KT, Sedivy SJ, Mack JD, Johnson MW, Burke LM, Williams MW, Katzelnick DJ, Sawchuk CN. Cognitive behavioral therapy for depressive disorders: Outcomes from a multi-state, multi-site primary care practice. J Affect Disord 2021;294:745-52. [PMID: 34375199 DOI: 10.1016/j.jad.2021.07.061] [Reference Citation Analysis]
51 Yan C, Rittenbach K, Souri S, Silverstone PH. Cost-effectiveness analysis of a randomized study of depression treatment options in primary care suggests stepped-care treatment may have economic benefits. BMC Psychiatry 2019;19:240. [PMID: 31382932 DOI: 10.1186/s12888-019-2223-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
52 Patten SB. Updated CANMAT Guidelines for Treatment of Major Depressive Disorder. Can J Psychiatry 2016;61:504-5. [PMID: 27534886 DOI: 10.1177/0706743716660034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
53 Burstein O, Doron R. The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice. J Vis Exp 2018. [PMID: 30417885 DOI: 10.3791/58184] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
54 Menear M, Dugas M, Careau E, Chouinard MC, Dogba MJ, Gagnon MP, Gervais M, Gilbert M, Houle J, Kates N, Knowles S, Martin N, Nease DE Jr, Zomahoun HTV, Légaré F. Strategies for engaging patients and families in collaborative care programs for depression and anxiety disorders: A systematic review. J Affect Disord 2020;263:528-39. [PMID: 31744737 DOI: 10.1016/j.jad.2019.11.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
55 McIntyre RS. The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatr Dis Treat 2017;13:2913-9. [PMID: 29238196 DOI: 10.2147/NDT.S150589] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
56 Levada OA, Troyan AS. Major depressive disorder and accelerated aging from a peripheral IGF-1 overexpression perspective. Medical Hypotheses 2020;138:109610. [DOI: 10.1016/j.mehy.2020.109610] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
57 Soares CN, Wajsbrot DB, Boucher M. Predictors of functional response and remission with desvenlafaxine 50 mg and 100 mg: a pooled analysis of randomized, placebo-controlled studies in patients with major depressive disorder. CNS Spectr 2020;25:363-71. [PMID: 31060632 DOI: 10.1017/S1092852919000828] [Reference Citation Analysis]
58 Lee Y, Brietzke E, Cao B, Chen Y, Linnaranta O, Mansur RB, Cortes P, Kösters M, Majeed A, Tamura JK, Lui LMW, Vinberg M, Keinänen J, Kisely S, Naveed S, Barbui C, Parker G, Owolabi M, Nishi D, Lee J, Srisurapanont M, Gill H, Guo L, Balanzá-Martínez V, Partonen T, Nolen WA, Lee JH, Kim JH, Chavannes NH, Ewais T, Atienza-Carbonell B, Silven AV, Yasuma N, Gil A, Novikov A, Lacey C, Versluis A, von Malortie S, Chan LF, Waqas A, Purgato M, Aardoom JJ, Ly-Uson JT, Sim K, Tuineag M, van der Kleij RMJJ, van Luenen S, Suttajit S, Hajek T, Lee YW, Porter RJ, Alsuwaidan M, Rosenblat JD, Ravindran AV, Lam RW, McIntyre RS; Global Alliance for Chronic Diseases (GACD) Mental Health Guidelines Working Group. Development and implementation of guidelines for the management of depression: a systematic review. Bull World Health Organ 2020;98:683-697H. [PMID: 33177758 DOI: 10.2471/BLT.20.251405] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
59 Scott KA, de Kloet AD, Smeltzer MD, Krause EG, Flak JN, Melhorn SJ, Foster MT, Tamashiro KLK, Sakai RR. Susceptibility or resilience? Prenatal stress predisposes male rats to social subordination, but facilitates adaptation to subordinate status. Physiol Behav 2017;178:117-25. [PMID: 28284881 DOI: 10.1016/j.physbeh.2017.03.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
60 Ng JY, Nazir Z, Nault H. Complementary and alternative medicine recommendations for depression: a systematic review and assessment of clinical practice guidelines. BMC Complement Med Ther 2020;20:299. [PMID: 33028320 DOI: 10.1186/s12906-020-03085-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
61 Enns MW, Mota N, Afifi TO, Bolton SL, Richardson JD, Patten SB, Sareen J. Course and Predictors of Major Depressive Disorder in the Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey: Cours et Prédicteurs du Trouble de Dépression Majeure Dans l'Enquête de Suivi Sur la Santé Mentale Auprès Des Membres des Forces Armées Canadiennes et des ex-Militaires. Can J Psychiatry 2021;:706743720984677. [PMID: 33406886 DOI: 10.1177/0706743720984677] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
62 Rush AJ, Aaronson ST, Demyttenaere K. Difficult-to-treat depression: A clinical and research roadmap for when remission is elusive. Aust N Z J Psychiatry 2019;53:109-18. [PMID: 30378447 DOI: 10.1177/0004867418808585] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
63 Katzman MA, Nierenberg AA, Wajsbrot DB, Meier E, Prieto R, Pappadopulos E, Mackell J, Boucher M. Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder. J Clin Psychopharmacol 2017;37:555-61. [PMID: 28817491 DOI: 10.1097/JCP.0000000000000775] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Tang Z, Feng S, Lin J. Depression and its correlation with social support and health-promoting lifestyles among Chinese university students: a cross-sectional study. BMJ Open 2021;11:e044236. [PMID: 34226212 DOI: 10.1136/bmjopen-2020-044236] [Reference Citation Analysis]
65 Guillaumie L, Ndayizigiye A, Beaucage C, Moisan J, Grégoire JP, Villeneuve D, Lauzier S. Patient perspectives on the role of community pharmacists for antidepressant treatment: A qualitative study. Can Pharm J (Ott) 2018;151:142-8. [PMID: 29531632 DOI: 10.1177/1715163518755814] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
66 Sinyor M, Schaffer A. The Lack of Adequate Scientific Evidence Regarding Physician-assisted Death for People with Psychiatric Disorders Is a Danger to Patients. Can J Psychiatry 2020;65:607-9. [PMID: 32452224 DOI: 10.1177/0706743720928658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Baune BT, Christensen MC. Differences in Perceptions of Major Depressive Disorder Symptoms and Treatment Priorities Between Patients and Health Care Providers Across the Acute, Post-Acute, and Remission Phases of Depression. Front Psychiatry 2019;10:335. [PMID: 31178765 DOI: 10.3389/fpsyt.2019.00335] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
68 Leclerc J, Lesage A, Rochette L, Huỳnh C, Pelletier É, Sampalis J. Prevalence of depressive, bipolar and adjustment disorders, in Quebec, Canada. J Affect Disord 2020;263:54-9. [PMID: 31818796 DOI: 10.1016/j.jad.2019.11.135] [Reference Citation Analysis]
69 Yu Y, Li Y, Qi K, Xu W, Wei Y. Rosmarinic acid relieves LPS-induced sickness and depressive-like behaviors in mice by activating the BDNF/Nrf2 signaling and autophagy pathway. Behav Brain Res 2022;433:114006. [PMID: 35843463 DOI: 10.1016/j.bbr.2022.114006] [Reference Citation Analysis]
70 Wang Z, Deng S, Lu H, Li L, Zhu X, Hu J, Xie H, Chen H, Chen Y, Zhang M, Fang Z, Wen Y, Shang D. Effect of venlafaxine dosage, valproic acid concentration, sex, and age on steady state dose‐corrected concentrations of venlafaxine and O ‐desmethylvenlafaxine: A retrospective analysis of therapeutic drug monitoring data in a Chinese population. Hum Psychopharmacol Clin Exp 2020;35. [DOI: 10.1002/hup.2733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Chokka P, Bougie J, Rampakakis E, Proulx J. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD). CNS Spectr 2019;24:338-47. [PMID: 29792585 DOI: 10.1017/S1092852918000913] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
72 Archer S, Chrenek C, Swainson J. Maintenance Ketamine Therapy for Treatment-Resistant Depression. J Clin Psychopharmacol 2018;38:380-4. [DOI: 10.1097/jcp.0000000000000894] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
73 Kapadia N, Zivanovic V, Moineau B, Downar J, Zariffa J, Popovic MR. Functional electrical stimulation of the facial muscles to improve symptoms in individuals with major depressive disorder: pilot feasibility study. Biomed Eng Online 2019;18:109. [PMID: 31727068 DOI: 10.1186/s12938-019-0730-6] [Reference Citation Analysis]
74 Hamel C, Lang E, Morissette K, Beck A, Stevens A, Skidmore B, Colquhoun H, LeBlanc J, Moore A, Riva JJ, Thombs BD, Colman I, Grigoriadis S, Nicholls SG, Potter BK, Ritchie K, Robert J, Vasa P, Lauria-Horner B, Patten S, Vigod SN, Hutton B, Shea BJ, Shanmugasegaram S, Little J, Moher D. Screening for depression in women during pregnancy or the first year postpartum and in the general adult population: a protocol for two systematic reviews to update a guideline of the Canadian Task Force on Preventive Health Care. Syst Rev 2019;8:27. [PMID: 30660183 DOI: 10.1186/s13643-018-0930-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
75 Cheng T. Late-Life Depression. In: Hategan A, Bourgeois JA, Hirsch CH, Giroux C, editors. Geriatric Psychiatry. Cham: Springer International Publishing; 2018. pp. 219-35. [DOI: 10.1007/978-3-319-67555-8_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
76 Wang G, Zhao K, Reynaud-Mougin C, Loft H, Ren H, Eriksen HF, Ettrup A. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder. Curr Med Res Opin 2020;36:875-82. [PMID: 31990207 DOI: 10.1080/03007995.2020.1723072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
77 Saragoussi D, Christensen MC, Hammer-Helmich L, Rive B, Touya M, Haro JM. Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study. Neuropsychiatr Dis Treat 2018;14:1339-50. [PMID: 29872301 DOI: 10.2147/NDT.S159276] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 7.8] [Reference Citation Analysis]
78 Grigolon RB, Trevizol AP, Gerchman F, Bambokian AD, Magee T, McIntyre RS, Gomes FA, Brietzke E, Mansur RB. Is Obesity A Determinant Of Success With Pharmacological Treatment For Depression? A Systematic Review, Meta-Analysis And Meta-Regression. J Affect Disord 2021;287:54-68. [PMID: 33773359 DOI: 10.1016/j.jad.2021.03.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Cho LL, Jones AA, Barbic S, Leonova O, Vila-rodriguez F, Buchanan T, Lang DJ, William Macewan G, Procyshyn RM, Panenka WJ, Barr AM, Thornton AE, Gicas KM, Honer WG. Psychometric properties and correlates of the Beck Depression Inventory in a community-based and homeless or precariously housed sample. Journal of Affective Disorders Reports 2021;6:100229. [DOI: 10.1016/j.jadr.2021.100229] [Reference Citation Analysis]
80 Salahudeen MS, Wright CM, Peterson GM. Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review. Ther Adv Drug Saf 2020;11:2042098620937899. [PMID: 32782779 DOI: 10.1177/2042098620937899] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
81 Zhao J, Liu H, Wu Z, Wang Y, Cao T, Lyu D, Huang Q, Wu Z, Zhu Y, Wu X, Chen J, Wang Y, Su Y, Zhang C, Peng D, Li Z, Rong H, Liu T, Xia Y, Hong W, Fang Y. Clinical features of the patients with major depressive disorder co-occurring insomnia and hypersomnia symptoms: a report of NSSD study. Sleep Med 2021;81:375-81. [PMID: 33813234 DOI: 10.1016/j.sleep.2021.03.005] [Reference Citation Analysis]
82 Choi W, Kang HJ, Kim JW, Kim HK, Kang HC, Lee JY, Kim SW, Stewart R, Kim JM. Predictive values of tumor necrosis factor-α for depression treatment outcomes: effect modification by hazardous alcohol consumption. Transl Psychiatry 2021;11:450. [PMID: 34475376 DOI: 10.1038/s41398-021-01581-7] [Reference Citation Analysis]
83 Lyndon GJ, Prieto R, Wajsbrot DB, Allgulander C, Bandelow B. Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity. Int Clin Psychopharmacol 2019;34:110-8. [PMID: 30870236 DOI: 10.1097/YIC.0000000000000256] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
84 St-Laurent T, Hammami R. The Untapped Potential of Ginsenosides and American Ginseng Berry in Promoting Mental Health via the Gut-Brain Axis. Nutrients 2022;14:2523. [PMID: 35745252 DOI: 10.3390/nu14122523] [Reference Citation Analysis]
85 Petrosyan Y, Sahakyan Y, Barnsley JM, Kuluski K, Liu B, Wodchis WP. Quality indicators for care of depression in primary care settings: a systematic review. Syst Rev 2017;6:126. [PMID: 28673356 DOI: 10.1186/s13643-017-0530-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
86 Guaiana G, Mastrangelo J, Hendrikx S, Barbui C. A Systematic Review of the Use of Telepsychiatry in Depression. Community Ment Health J 2021;57:93-100. [PMID: 33040191 DOI: 10.1007/s10597-020-00724-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
87 Xiao Y, Zhao L, Wang D, Xue SW, Tan Z, Lan Z, Kuai C, Wang Y, Li H, Pan C, Fu S, Hu X. Effective Connectivity of Right Amygdala Subregions Predicts Symptom Improvement Following 12-Week Pharmacological Therapy in Major Depressive Disorder. Front Neurosci 2021;15:742102. [PMID: 34588954 DOI: 10.3389/fnins.2021.742102] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Christensen MC, Ren H, Fagiolini A. Emotional blunting in patients with depression. Part I: clinical characteristics. Ann Gen Psychiatry 2022;21:10. [PMID: 35379283 DOI: 10.1186/s12991-022-00387-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
89 Chow TK, Kennedy S, Rizvi SJ. Anhedonia as a Crucial Factor of Depression: Assessment, Neurobiological Underpinnings and Treatment. In: Kim Y, editor. Understanding Depression. Singapore: Springer; 2018. pp. 99-112. [DOI: 10.1007/978-981-10-6577-4_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
90 Wang M, Wang J, Wang Y, Huang X, Huang Y, Huang J, Feng Y, Li X. Reliability and validity of the Mental Health Self-management Questionnaire among Chinese patients with mood and anxiety disorders. Front Psychiatry 2022;13:952951. [DOI: 10.3389/fpsyt.2022.952951] [Reference Citation Analysis]
91 Hong RH, Murphy JK, Michalak EE, Chakrabarty T, Wang Z, Parikh SV, Culpepper L, Yatham LN, Lam RW, Chen J. Implementing Measurement-Based Care for Depression: Practical Solutions for Psychiatrists and Primary Care Physicians. Neuropsychiatr Dis Treat 2021;17:79-90. [PMID: 33469295 DOI: 10.2147/NDT.S283731] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
92 Baune BT, Florea I, Ebert B, Touya M, Ettrup A, Hadi M, Ren H. Patient Expectations and Experiences of Antidepressant Therapy for Major Depressive Disorder: A Qualitative Study. Neuropsychiatr Dis Treat 2021;17:2995-3006. [PMID: 34588779 DOI: 10.2147/NDT.S325954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
93 Ayyash A, Holloway AC. Fluoxetine-induced hepatic lipid accumulation is mediated by prostaglandin endoperoxide synthase 1 and is linked to elevated 15-deoxy-Δ12,14 PGJ2. J Appl Toxicol 2021. [PMID: 34897744 DOI: 10.1002/jat.4272] [Reference Citation Analysis]
94 Christensen MC, Wong CMJ, Baune BT. Symptoms of Major Depressive Disorder and Their Impact on Psychosocial Functioning in the Different Phases of the Disease: Do the Perspectives of Patients and Healthcare Providers Differ? Front Psychiatry 2020;11:280. [PMID: 32390877 DOI: 10.3389/fpsyt.2020.00280] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Hein M, Mungo A, Loas G. Nonremission After Electroconvulsive Therapy in Individuals With Major Depression: Role of Borderline Personality Disorder. J ECT 2022. [PMID: 35482914 DOI: 10.1097/YCT.0000000000000857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Majeed A, Xiong J, Teopiz KM, Ng J, Ho R, Rosenblat JD, Phan L, Cao B, McIntyre RS. Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials. Expert Opin Emerg Drugs 2021;26:63-74. [PMID: 33682569 DOI: 10.1080/14728214.2021.1898588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Smith KL, Cunningham JI, Eyerman DJ, Dean RL, Deaver DR, Sanchez C. Opioid system modulators buprenorphine and samidorphan alter behavior and extracellular neurotransmitter concentrations in the Wistar Kyoto rat. Neuropharmacology 2019;146:316-26. [DOI: 10.1016/j.neuropharm.2018.11.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
98 Lauzier S, Guillaumie L, Humphries B, Grégoire JP, Moisan J, Villeneuve D. Reprint of: Psychosocial factors associated with pharmacists' antidepressant drug treatment monitoring. J Am Pharm Assoc (2003) 2020;60:S34-43. [PMID: 32977929 DOI: 10.1016/j.japh.2020.08.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Turna J, Patterson B, Van Ameringen M. Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Depress Anxiety 2017;34:1006-17. [PMID: 28636769 DOI: 10.1002/da.22664] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 8.6] [Reference Citation Analysis]
100 Benrimoh D, Tanguay-Sela M, Perlman K, Israel S, Mehltretter J, Armstrong C, Fratila R, Parikh SV, Karp JF, Heller K, Vahia IV, Blumberger DM, Karama S, Vigod SN, Myhr G, Martins R, Rollins C, Popescu C, Lundrigan E, Snook E, Wakid M, Williams J, Soufi G, Perez T, Tunteng JF, Rosenfeld K, Miresco M, Turecki G, Gomez Cardona L, Linnaranta O, Margolese HC. Using a simulation centre to evaluate preliminary acceptability and impact of an artificial intelligence-powered clinical decision support system for depression treatment on the physician-patient interaction. BJPsych Open 2021;7:e22. [PMID: 33403948 DOI: 10.1192/bjo.2020.127] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
101 Fonseka TM, Pong JT, Kcomt A, Kennedy SH, Parikh SV. Collaborating with individuals with lived experience to adapt CANMAT clinical depression guidelines into a patient treatment guide: The CHOICE-D co-design process. J Eval Clin Pract 2020;26:1259-69. [PMID: 31729117 DOI: 10.1111/jep.13308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
102 Hershenberg R, Mcdonald WM, Crowell A, Riva-posse P, Craighead WE, Mayberg HS, Dunlop BW. Concordance between clinician-rated and patient reported outcome measures of depressive symptoms in treatment resistant depression. Journal of Affective Disorders 2020;266:22-9. [DOI: 10.1016/j.jad.2020.01.108] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
103 Mattingly GW, Ren H, Christensen MC, Katzman MA, Polosan M, Simonsen K, Hammer-helmich L. Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study. Front Psychiatry 2022;13:824831. [DOI: 10.3389/fpsyt.2022.824831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Kamath J, Leon Barriera R, Jain N, Keisari E, Wang B. Digital phenotyping in depression diagnostics: Integrating psychiatric and engineering perspectives. World J Psychiatry 2022; 12(3): 393-409 [PMID: 35433319 DOI: 10.5498/wjp.v12.i3.393] [Reference Citation Analysis]
105 Ilie G, Rutledge R, Sweeney E. Anxiety and depression symptoms in adult males in Atlantic Canada with or without a lifetime history of prostate cancer. Psychooncology 2020;29:280-6. [PMID: 31652379 DOI: 10.1002/pon.5244] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
106 Christensen MC, Ren H, Fagiolini A. Emotional blunting in patients with depression. Part II: relationship with functioning, well-being, and quality of life. Ann Gen Psychiatry 2022;21:20. [PMID: 35725552 DOI: 10.1186/s12991-022-00392-4] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
107 Jeng J, Li C, Lin H, Tsai S, Bai Y, Su T, Chang Y, Cheng C. Antidepressant-resistant depression is characterized by reduced short- and long-interval cortical inhibition. Psychol Med 2020;50:1285-91. [DOI: 10.1017/s0033291719001223] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
108 Roberge P, Houle J, Provost JR, Coulombe S, Beaudin A, Bower P, Lemyre FC, Drapeau M, Drouin MS, Hudon C, Provencher MD, Vasiliadis HM. A pragmatic randomized controlled trial of a group self-management support program versus treatment-as-usual for anxiety disorders: study protocol. BMC Psychiatry 2022;22:135. [PMID: 35189848 DOI: 10.1186/s12888-021-03675-4] [Reference Citation Analysis]
109 Samokhvalov AV. Theory and Practice of Treatment of Concurrent Major Depressive and Alcohol Use Disorders: 7 Lessons from Clinical Practice and Research. Canadian Journal of Addiction 2021;12:39-46. [DOI: 10.1097/cxa.0000000000000125] [Reference Citation Analysis]
110 Wang Z, Ma X, Xiao C. Standardized Treatment Strategy for Depressive Disorder. Adv Exp Med Biol 2019;1180:193-9. [PMID: 31784964 DOI: 10.1007/978-981-32-9271-0_10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
111 Dores AK, Fick GH, MacMaster FP, Williams JVA, Bulloch AGM, Patten SB. Outdoor Air Pollution and Depression in Canada: A Population-Based Cross-Sectional Study from 2011 to 2016. Int J Environ Res Public Health 2021;18:2450. [PMID: 33801515 DOI: 10.3390/ijerph18052450] [Reference Citation Analysis]
112 Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study. CNS Spectr 2019;24:616-27. [PMID: 30802419 DOI: 10.1017/S1092852919000786] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
113 Abou El-Magd RM, Obuobi-Donkor G, Adu MK, Lachowski C, Duddumpudi S, Lawal MA, Sapara AO, Achor M, Kouzehgaran M, Hegde R, Chew C, Mach M, Daubert S, Urichuk L, Snaterse M, Surood S, Li D, Greenshaw A, Agyapong VIO. Repetitive Transcranial Magnetic Stimulation With and Without Internet-Delivered Cognitive-Behavioral Therapy for the Treatment of Resistant Depression: Protocol for Patient-Centered Randomized Controlled Pilot Trial. JMIR Res Protoc 2020;9:e18843. [PMID: 33107835 DOI: 10.2196/18843] [Reference Citation Analysis]
114 Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Gilbert A, Burns L, Jablonski MR, Dechairo B. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res 2019;111:59-67. [PMID: 30677646 DOI: 10.1016/j.jpsychires.2019.01.003] [Cited by in Crossref: 89] [Cited by in F6Publishing: 77] [Article Influence: 29.7] [Reference Citation Analysis]
115 Brancati GE, Tripodi B, Novi M, Barbuti M, Medda P, Perugi G. Association of treatment facets, severity of manic symptoms, psychomotor disturbances and psychotic features with response to electroconvulsive therapy in bipolar depression. World J Biol Psychiatry 2021;22:194-202. [PMID: 32490697 DOI: 10.1080/15622975.2020.1770860] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
116 Chokka P, Tvistholm AH, Bougie J, Clerzius G, Ettrup A. Improvements in Workplace Productivity in Working Patients With Major Depressive Disorder: Results From the AtWoRC Study. J Occup Environ Med 2020;62:e94-e101. [PMID: 31895735 DOI: 10.1097/JOM.0000000000001805] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
117 Sander C, Ueck P, Mergl R, Gordon G, Hegerl U, Himmerich H. Physical activity in depressed and non-depressed patients with obesity. Eat Weight Disord 2018;23:195-203. [PMID: 28188598 DOI: 10.1007/s40519-016-0347-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
118 Morita Y, Miyamoto Y, Takano A, Kawakami N, Coulombe S. Reliability and validity of the Japanese version of the Mental Health Self-management Questionnaire among people with mental illness living in the community. BMC Psychol 2019;7:30. [PMID: 31118086 DOI: 10.1186/s40359-019-0301-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]